Among 163 patients carrying the UGT1A1*1*28 or UGT1A1*1*1 genotypes treated with upfront reduced doses of irinotecan following clinical judgment, 25 (15.3%) developed grade ≥ 3 neutropenia. This evidence concerns the gene UGT1A1 and Decreased total neutrophil count.